Physician profile
Gerald Wayne Mank
NPI 1821309592
$756.03
in general payments reported to CMS, 2019-2025
10 companies · $81.59 in 2025
The $81.59 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.90 · 2020: $55.91 · 2021: $318 · 2022: $37.92 · 2023: $22.19 · 2024: $222 · 2025: $81.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $325.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $300.77 | 2021-2025 | Exalt Model D, General - Biliary Devices |
| Braintree Laboratories, INC. | $165.07 | 2020-2021 | |
| Olympus America INC. | $67.60 | 2024-2025 | Single Use Repositionable Clip, Olympus |
| Janssen Biotech, INC. | $67.00 | 2021 | |
| Nestle Healthcare Nutrition INC. | $36.60 | 2022-2023 | |
| Ambu INC. | $34.92 | 2021 | |
| Phathom Pharmaceuticals, INC. | $25.81 | 2025 | Voquezna |
| Covidien LP | $20.36 | 2020 | |
| Madrigal Pharmaceuticals | $19.00 | 2024 | Resmetirom |
| Endogastric Solutions, INC | $18.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Mank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.